A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
Public ClinicalTrials.gov record NCT04818346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo
Study identification
- NCT ID
- NCT04818346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Interventions
- INCB054707 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2021
- Primary completion
- May 23, 2022
- Completion
- May 23, 2023
- Last update posted
- Apr 10, 2024
2021 – 2023
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site 010 | Hoover | Alabama | 35244 | — |
| Investigative Site 015 | Gilbert | Arizona | 85295 | — |
| Investigative Site 028 | Scottsdale | Arizona | 85260 | — |
| Investigative Site 006 | Irvine | California | 92697 | — |
| Investigative Site 009 | Los Angeles | California | 90036 | — |
| Investigative Site 018 | Los Angeles | California | 90045 | — |
| Investigative Site 017 | Sacramento | California | 95815 | — |
| Investigative Site 032 | Orange Park | Florida | 32073 | — |
| Investigative Site 005 | Tampa | Florida | 33613 | — |
| Investigative Site 022 | Tampa | Florida | 33614 | — |
| Investigative Site 011 | West Palm Beach | Florida | 33401 | — |
| Investigative Site 024 | Covington | Louisiana | 70433 | — |
| Investigative Site 002 | Brighton | Massachusetts | 02135 | — |
| Investigative Site 023 | Saint Paul | Minnesota | 55112 | — |
| Investigative Site 027 | Verona | New Jersey | 07044 | — |
| Investigative Site 003 | Columbus | Ohio | 43215 | — |
| Investigative Site 007 | Norman | Oklahoma | 73071 | — |
| Investigative Site 001 | Portland | Oregon | 97223 | — |
| Investigative Site 021 | Plymouth Meeting | Pennsylvania | 19462 | — |
| Investigative Site 004 | Murfreesboro | Tennessee | 37130 | — |
| Investigative Site 033 | Dallas | Texas | 75230 | — |
| Investigative Site 012 | San Antonio | Texas | 78213 | — |
| Investigative Site 030 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04818346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 10, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04818346 live on ClinicalTrials.gov.